“Australian Biotech EnGenelC , which is developing its nanocell tech for use in infectious diseases (including a covid 19 vaccine ) as well as a cancer treatment , has announced a deal with US biotech ImmunityBio to develop, manufacture, and commercialize the tech .”
EnGenelC will grant immunityBio an exclusive , worldwide license for development through to commercialization of its EngenelC dream vector in combination with its anti cancer drugs and covid 19 vaccine. They will also build facilities not only in the US but in South Africa as well.
EngenelC also believes the vaccine will be effective against mutants, as well as having the logistical advantages of one year of shelf-life and room temperature storage.” The EDV tech also “targets and effectively kills cancer cells with minimal toxicity , while stimulation on antitumor immune response.”
-jade zuniga
Comments